Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | GABRP | O00591 | 1/20 | 0.83 |
| ▸ | GABRD | O14764 | 1/20 | 0.83 |
| ▸ | PIM1 | P11309 | 1/20 | 0.83 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.83 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.83 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pectolinarigenin SCHEMBL243686 | 1.00 | MAPT (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL8063178 | 0.91 | FLT3 (0.83) | MAPTFLT3MEN1KMT2ANPC1 | |
| Hispidulin SCHEMBL514926 | 0.91 | POLB (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| Hispidulin SCHEMBL29458970 | 0.91 | POLB (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL28732976 | 0.90 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL29504103 | 0.90 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL6242511 | 0.90 | KMT2A (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL737628 | 0.89 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| Salvigenin SCHEMBL1427018 | 0.89 | FLT3 (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL18601886 | 0.89 | FLT3 (0.80) | MAPTFLT3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4709365-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709365-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709365-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025144990-A1 | METHODS AND COMPOSITIONS FOR BIOPRODUCTION OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2025-07-03 | — | — | WO | disclosed |
| WO-2024233739-A3 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024233739-A3 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024233739-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233739-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233739-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118121650-A | Traditional Chinese medicine extract, preparation method thereof and blood component detection method | 川北医学院 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023127826-A1 | ELECTROLYTIC CAPACITOR AND LIQUID COMPONENT FOR ELECTROLYTIC CAPACITOR | パナソニックＩＰマネジメント株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| CN-114432356-A | A composition for treating cancer and its preparation method | 庞德东 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | TXN2, SMN1; SMN2, SNCA | MAPT 33/4885FLT3 4755/4885MEN1 4241/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | MAPT 11/4885FLT3 4609/4885MEN1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.